These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39098109)

  • 1. The potential role of lung microbiota and lauroylcarnitine in T-cell activation associated with checkpoint inhibitor pneumonitis.
    Yu W; Wang K; He Y; Shang Y; Hu X; Deng X; Zhao L; Ma X; Mu X; Li R; Gao Z
    EBioMedicine; 2024 Aug; 106():105267. PubMed ID: 39098109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis.
    Yu W; He Y; Shang Y; Guo T; Wang K; Liang H; Xue J; Ma X; Mu X; Li R; Gao Z
    Clin Immunol; 2023 Feb; 247():109230. PubMed ID: 36646189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence.
    Guo C; Zhang Q; Zhou P; Cheng Y; Nie L; Wang G
    Sci Rep; 2024 Jul; 14(1):17137. PubMed ID: 39060280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
    Zhang Q; Tang L; Zhou Y; He W; Li W
    Front Immunol; 2021; 12():663986. PubMed ID: 34122422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predict factors and clinical prognosis value of immune-related pneumonia of receiving PD-1 inhibitor in advanced non-small cell lung cancer: A retrospective study.
    Yang J; Lyu M; Feng X; Liu F; Zeng R; Sun X; Bao Z; Zhou L; Gao B; Ni L; Xiang Y
    Int Immunopharmacol; 2024 Dec; 142(Pt B):113140. PubMed ID: 39312858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis.
    Chen R; Shi Y; Fang N; Shao C; Huang H; Pan R; Xu Y; Wang M; Liu X; Xu K; Zhu R; Wang M
    Cancer Immunol Immunother; 2024 Sep; 73(11):235. PubMed ID: 39271538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
    Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
    Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
    Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
    Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
    Front Immunol; 2021; 12():818492. PubMed ID: 35095920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
    Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
    Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
    Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
    Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.
    Suresh K; Naidoo J; Zhong Q; Xiong Y; Mammen J; de Flores MV; Cappelli L; Balaji A; Palmer T; Forde PM; Anagnostou V; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Lin CT; Feller-Kopman D; Lerner AD; Lee H; Shafiq M; Yarmus L; Lipson EJ; Soloski M; Brahmer JR; Danoff SK; D'Alessio F
    J Clin Invest; 2019 Jul; 129(10):4305-4315. PubMed ID: 31310589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
    Hu X; Ren J; Xue Q; Luan R; Ding D; Tan J; Su X; Yang J
    Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37681488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory.
    Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L
    Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
    Li X; Yang F; Liu B; Ye L; Du J; Fan X; Yu Y; Li M; Bu L; Zhang Z; Xie L; Li W; Qi J
    J Immunother; 2024 Jul-Aug 01; 47(6):220-226. PubMed ID: 38618919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
    BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.